The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations.
about
Erythropoiesis-stimulating agents for anaemia in chronic heart failure patientsErythropoietin in the critically ill - is it more than just blood?Heart failure in patients with chronic kidney disease: a systematic integrative reviewPharmacologic management of chronic reno-cardiac syndromeThe importance of anemia and its correction in the management of severe congestive heart failureThe cardio renal anemia syndrome: correcting anemia in patients with resistant congestive heart failure can improve both cardiac and renal function and reduce hospitalizationsPharmacotherapy for comorbidities in chronic heart failure: a focus on hematinic deficiencies, diabetes mellitus and hyperkalemia.Anemia management in heart failure: a thick review of thin data.Prognostic significance of anaemia in patients with heart failure with preserved and reduced ejection fraction: results from the MAGGIC individual patient data meta-analysis.Anemia and chronic kidney disease are associated with poor outcomes in heart failure patients.A randomized controlled study comparing once-weekly to every-2-week and every-4-week dosing of epoetin alfa in CKD patients with anemia.Managing anemia in patients with chronic heart failure: what do we know?Anemia is independently associated with NT-proBNP levels in asymptomatic predialysis patients with chronic kidney disease.Epidemiology of chronic kidney disease in heart failure.The role of erythropoietin stimulating agents in anemic patients with heart failure: solved and unresolved questionsPreoperative hemoglobin and outcomes in patients with CKD undergoing cardiac surgeryImpact of chronic kidney disease and anemia on physical function in patients with chronic heart failure.Cost-utility of ferric carboxymaltose (Ferinject®) for iron-deficiency anemia patients with chronic heart failure in South Korea.The pathological consequences of anaemia.The cardiorenal syndrome: making the connection.Anaemia and long term mortality in heart failure patients: a retrospective study.Association of anaemia in primary care patients with chronic kidney disease: cross sectional study of quality improvement in chronic kidney disease (QICKD) trial data.Cardiovascular abnormalities and hypertension in the elderly dialysis patient.Influence of progressive renal dysfunction in chronic heart failure.New developments in the pharmacological treatment of chronic heart failure.Anemia and heart failure: a cause of progression or only a consequence?Novel pharmacological treatments for heart failure.Anaemia in chronic heart failure: what is its frequency in the UK and its underlying causes?Anemia, cancer, and aging.The cardio-renal-anaemia syndrome predicts survival in peritoneally dialyzed patientsAnaemia is associated with higher mortality among patients with heart failure with preserved systolic functionThe Relationship between Anemia and the Initiation of Dialysis in Patients with Type 2 Diabetic Nephropathy.Low-Dose Treatment with Erythropoiesis-Stimulating Agents and Cardiovascular Geometry in Chronic Kidney Disease: Is Darbepoetin-α More Effective than Expected?Anemia in heart failure patientsMechanisms and treatment of anemia in chronic heart failure.Use of erythropoietin in heart failure management.Anemia as an Independent Predictor of Adverse Cardiac Outcomes in Patients with Atrial FibrillationPrevalence of anaemia among patients with heart failure at the Brazzaville University HospitalA novel protective effect of erythropoietin in the infarcted heartCirculating selenium and carboxymethyl-lysine, an advanced glycation endproduct, are independent predictors of anemia in older community-dwelling adults
P2860
Q24241045-792C5C0C-A10C-4A5C-89FC-D550CBFA4567Q24800397-B9358345-223A-4E6C-82B8-2159C87EE822Q26824149-0F5A4884-D8AA-4392-B6A8-3092881AF002Q26829812-51BFB5E6-3BD2-44E5-8436-7F15D962F852Q28194293-26F715A2-2F0E-4BA6-A52C-CFA2364CFF8AQ28208693-0B900F71-A92B-49FF-A40F-C4B275F3BE18Q30250020-EF40FB0D-B15A-45D9-B3C2-48642E1B3E3EQ30940154-760479D5-3CC5-4391-8157-AA433CB98A22Q30952502-9DF5682F-00AF-467C-9A46-A3875AF90C99Q33235437-EF7C24FF-EE9C-4957-ADBA-477FCCC312F0Q33770093-A447EE79-1418-4C0C-8554-C923D3DA7FEDQ33797640-E835FE9D-7FBF-4ECB-A4C6-20ED22196AFBQ33899258-5702DA6A-9A93-4F85-BF25-169ACD791F99Q33978466-F551F360-819B-400E-8428-DD11181A6D50Q34065957-ED5B0DB8-D16C-403F-853C-3DD2EF0BFD89Q34124684-C498A046-0F38-4068-9BC4-5330E2CAAA24Q34181266-2A2FD404-964E-4643-926D-C28B12797295Q34200064-A8F8115E-83EF-4825-9FA1-59B052D9C605Q34291421-0442B356-AD70-46A0-9E95-458E826AD8D7Q34340391-189B8AF6-A9CC-4B56-86E8-1B15064C6CADQ34406816-602CE490-73A1-4CFC-9906-50F0F045F9BCQ34564073-4EF141B1-B21C-4B55-A163-C69BF3685FDCQ34600815-67F3BE7C-03BA-41AF-B82A-FDADAF69DA88Q34604651-1920D538-3157-4BB0-8FEE-68FCC404B222Q35117060-F9EBF6FA-9D53-4AC3-8661-D98804B246FBQ35252704-45080333-2A93-4CDD-84D1-6F0350B8941AQ35570949-1DD1ABDE-A731-4311-AE1F-29EA8FABB667Q35579818-52E21F67-AC2F-460C-8C3C-55BE6A99D830Q35599070-81AB39AF-946F-4B2B-A0C0-1F394D822AADQ35770743-7AC32306-4043-4980-BD1A-FAD9AA00A04EQ35770879-CE971011-53C5-4BE9-8CCC-EF766DCDA06AQ35790645-0B9D745A-7080-4753-ACBB-B8F19D36B3F2Q35868691-C3409566-CFCA-4959-9827-0C94F9C167BDQ35872198-2B0898C3-E5F1-4327-BDF8-B4AFE00A2B21Q35911432-F91CBC7C-FCD4-4FCF-89EF-E69A5449DD22Q35923151-B74C04F2-FE86-452A-AE6E-93BEDB2E1603Q35942115-C4A2BFF5-7BFB-4664-8209-CB9D56BB30D0Q35962136-0655A4FE-66B5-4E96-A06B-1FD64ED315B3Q36001255-C910A960-26CF-4D92-AB25-EE98E758D8AEQ36040868-5DBB1DE4-CDD0-4011-9441-E4882C618422
P2860
The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
The use of subcutaneous erythr ...... edly reduces hospitalizations.
@en
The use of subcutaneous erythr ...... edly reduces hospitalizations.
@nl
type
label
The use of subcutaneous erythr ...... edly reduces hospitalizations.
@en
The use of subcutaneous erythr ...... edly reduces hospitalizations.
@nl
prefLabel
The use of subcutaneous erythr ...... edly reduces hospitalizations.
@en
The use of subcutaneous erythr ...... edly reduces hospitalizations.
@nl
P2093
P921
P1476
The use of subcutaneous erythr ...... edly reduces hospitalizations.
@en
P2093
Leibovitch E
P304
P356
10.1016/S0735-1097(00)00613-6
P407
P577
2000-06-01T00:00:00Z